Categorical #1: Application of Advances in Radionuclide Cardiovascular Imaging
It has been four years since the last categorical seminar on Molecular Imaging of Infection and Inflammation, and there have been many new developments in the interim. This session is designed for imaging specialists, investigators, technologists, and clinicians, who want a review of the current status of molecular imaging of inflammation and infection as well as updates on new and evolving developments in the field. In addition to a review of currently available single photon and positron emitting radiopharmaceuticals, this seminar will highlight the role of molecular imaging in fever of unknown origin, cardiovascular and musculoskeletal infections, pediatric infections, sarcoid, rheumatologic diseases, and COVID-19. Recent advances including infection specific radiopharmaceuticals, PET/MRI and AI in infection and inflammation will also be covered. Molecular imaging of inflammation and infection is an expanding field, with many novel developments occurring. This categorical seminar will offer a combination of topics relevant to current clinical practice together with a look into the future of the field.

Categorical #2: PSMA PET and Radioligand Therapy
Sponsored by the SNMMI Correlative Imaging Council and Therapy Center of Excellence
This session will review the role of PSMA for both imaging and therapy in patients with prostate cancer.  We will a review of PSMA PET at initial staging and biochemical recurrence, focusing on interpretation and appropriate use.  We will provide an overview of the treatment landscape of castration sensitive and resistant prostate cancer.  A review of the prospective trials evaluating 177Lu-based PSMA radioligand therapies will be provided, with an overview on how to use PSMA PET and other imaging to select patients for treatment.  We will discuss the hurdles of setting of a PSMA RLT clinic, and how a multidisciplinary team can be assembled to provide the optimal care for patients.  We will conclude with a tumor board discussing difficult cases for PSMA radioligand therapy.

Categorical #3: Molecular Imaging of Inflammation and Infection: Today and Tomorrow
Sponsored by the SNMMI General Clinical Nuclear Medicine Council
It has been four years since the last categorical seminar on Molecular Imaging of Infection and Inflammation, and there have been many new developments in the interim.  This session is designed for imaging specialists, investigators, technologists, and clinicians, who want a review of the current status of molecular imaging of inflammation and infection as well as updates on new and evolving developments in the field. In addition to a review of currently available single photon and positron emitting radiopharmaceuticals, this seminar will highlight the role of molecular imaging in fever of unknown origin, cardiovascular and musculoskeletal infections, pediatric infections, sarcoid, rheumatologic diseases, and COVID-19. Recent advances including infection specific radiopharmaceuticals, PET/MRI and AI in infection and inflammation will also be covered. Molecular imaging of inflammation and infection is an expanding field, with many novel developments occurring. This categorical seminar will offer a combination of topics relevant to current clinical practice together with a look into the future of the field.

Categorical #4: Boost Your Brain Metabolism & Knowledge with Interactive Difficult & Interesting Nuclear Medicine Cases
Sponsored by the SNMMI Academic Council, Advanced Associate Council, Early Career Professionals, General Clinical Nuclear Medicine Council, Pediatric Council and PET Center of Excellence
This categorical session is intended for all Nuclear Medicine professionals no matter the stage of their training or career. The purpose of this session is to bring together the experience and knowledge from multiple councils and centers within the SNMMI to present a case-based predominately head to feet review of both difficult and/or interesting cases that we may all at some point encounter. The format will be where both live and virtual attendees can participate. Those registered for this course will be encouraged to bring their own device (BYOD) to interact with each of the cases presented. Each case will have an interactive component which can include polling, interactive imaging with participant tools such as drawing and circling items, short videos, and more which will be shared via internet for access on everyone’s own device. We wish to utilize this new meeting format to help reinforce or enhance knowledge of common/uncommon and interesting or difficult nuclear medicine studies, encourage high audience participation, hopefully provide longer retention of what is learned or reinforced, and or course, to bring more interest and “fun” to this educational process.

Categorical #5: New Advancements in Brain Molecular Imaging
Sponsored by the SNMMI Brain Imaging Council
The proposed session will cover new advancements in Molecular Brain Imaging. Sessions will include talks covering both basic science and new advancements in brain molecular imaging as well as updates for the use of neuroimaging in the clinic.  The intended audience is both experienced clinicians as well as early career level scientists and physicians who wish to expand their knowledge of molecular neuroimaging. Attendees will gain a better understanding of clinical applications of brain imaging including updated appropriate use criteria for amyloid imaging, standard imaging tools such as FDG-PET and the use of biomarkers in the clinical evaluation of dementing disorders. In addition, exciting new research developments such as synaptic imaging in neurodegenerative conditions, novel tracers and neurotheranostics will be presented.

Categorical #6: From Design to Dose of Therapeutic Radiopharmaceuticals: Practical Aspects and Challenges
Sponsored by the SNMMI

Categorical #7: Molecular Imaging of Immunotherapy Response
Sponsored by the Center for Molecular Imaging Innovation and Translation
Immunotherapy has revolutionized the cancer treatment landscape, providing hope for durable treatment responses and even a cure for cancer, though these treatments are not equally effective across all cancer types. Experience in the imaging appearance of immunotherapy response and side effects with conventional imaging modalities has grown significantly. However, biomarkers that can provide more specific information regarding the immune response would improve our ability to assess response specifically as well as advance our understanding of the mechanisms that lead to most effective treatment responses. This is of particular interest for the field of nuclear medicine because there are emerging data that immunotherapy may be synergistic with targeted radionuclide therapies. Therefore, there is a pressing need to develop new imaging biomarkers that accurately measure the activity of the immune response.  The goal of this session is to provide the audience with an overview of the immunotherapy agents in clinical practice and  what should be considered when monitoring these therapies with routine imaging modalities such as FDG PET, CT, and MRI. In addition,  a summary of specific molecular imaging approaches being developed to monitor immune responses, including T-cell targeted and macrophage/monocyte imaging approaches, and novel imaging analytic approaches will be provided. The session will also discuss how these novel approaches could enable nuclear medicine to contribute to the improvement of treatment outcomes for patients treated with immunotherapy.